RM
Rubi Mukhopadhyay
About Rubi Mukhopadhyay
Data last updated:
Rubi Mukhopadhyay is a Director at Allenburys Pharma Limited (since 2020), Director at Alventa Pharma Limited (since 2018) and Director at Aleris Pharmaceuticals Limited (since 2021), and holds 2 more current directorships. The companies operate in Pharma and Financial Services. The 5 current companies with reported revenue have a combined latest revenue of ₹426 Cr; the largest is Allenburys Pharma Limited at ₹159 Cr (FY 2025). Earlier, Rubi Mukhopadhyay was an Additional Director at Gayatri Ensemble Private Limited (2018–2025) and Director at Concept Biosciences India Private Limited (2018–2019).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Allenburys Pharma Limited U93020WB2020PLC240519 | Director | 15 Oct 2020 | 2020 | ₹159 Cr (FY 2025) | Active |
 Alventa Pharma Limited U24299WB2016PLC225674 | Director | 04 Jun 2018 | 2016 | ₹143 Cr (FY 2025) | Active |
| Aleris Pharmaceuticals Limited U24304WB2021PLC245141 | Director | 13 May 2021 | 2021 | ₹75.07 Cr (FY 2025) | Active |
| Elder Laboratories Limited U24309WB2021PLC245140 | Director | 13 May 2021 | 2021 | ₹49.51 Cr (FY 2024) | Active |
| Nicholas Pharma India Limited U85100WB2021PLC244244 | Director | 30 Mar 2021 | 2021 | ₹40,000 (FY 2023) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Gayatri Ensemble Private Limited U17120WB2008PTC130826 | Additional Director | 03 Oct 2018 | 2008 | ₹5 Lakh (FY 2022) | Active |
| Concept Biosciences India Private Limited U85190WB2008PTC127172 | Director | 20 Apr 2018 | 2008 | ₹114 Cr (FY 2019) | Under Liquidation |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Rubi Mukhopadhyay
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anand Kumar Parmanandka | 08518622 | Allenburys Pharma Limited , Alventa Pharma Limited and 3 more | Director |
| Biswajit Pan | 08473723 | Allenburys Pharma Limited , Alventa Pharma Limited and 3 more | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rubi Mukhopadhyay
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rubi Mukhopadhyay
Rubi Mukhopadhyay currently holds 5 directorships: Allenburys Pharma Limited (Director, since 15 Oct 2020, revenue ₹159 Cr (FY 2025)); Alventa Pharma Limited (Director, since 04 Jun 2018, revenue ₹143 Cr (FY 2025)); Aleris Pharmaceuticals Limited (Director, since 13 May 2021, revenue ₹75.07 Cr (FY 2025)); Elder Laboratories Limited (Director, since 13 May 2021, revenue ₹49.51 Cr (FY 2024)); Nicholas Pharma India Limited (Director, since 30 Mar 2021, revenue ₹40,000 (FY 2023)).
Rubi Mukhopadhyay was first appointed on 20 Apr 2018 as Director at Concept Biosciences India Private Limited. The most recent appointment on record is 13 May 2021 at Elder Laboratories Limited.
The 5 current companies of Rubi Mukhopadhyay that report revenue have a combined latest revenue of ₹426 Cr: Allenburys Pharma Limited ₹159 Cr (FY 2025); Alventa Pharma Limited ₹143 Cr (FY 2025); Aleris Pharmaceuticals Limited ₹75.07 Cr (FY 2025); Elder Laboratories Limited ₹49.51 Cr (FY 2024); Nicholas Pharma India Limited ₹40,000 (FY 2023).
Rubi Mukhopadhyay held 2 earlier board appointments: Gayatri Ensemble Private Limited (Additional Director, 03 Oct 2018 to 26 Sep 2025); Concept Biosciences India Private Limited (Director, 20 Apr 2018 to 04 Jul 2019).
The current boards of Rubi Mukhopadhyay's companies include Anand Kumar Parmanandka (Allenburys Pharma Limited), Biswajit Pan (Allenburys Pharma Limited).